Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®?(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
CRYSVITA is the first approved biologic treatment in the EU for patients with TIO who cannot undergo surgical removal of...

















